Dividend Assets Capital’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Dividend Assets Capital’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-4,000	Closed	-$42K	–	566
2023 Q1	$42K	Hold	4,000	–	–	0.01%	301
2022 Q4	$42K	Hold	4,000	–	–	0.01%	301
2022 Q3	$18K	Hold	4,000	–	–	﹤0.01%	387
2022 Q2	$16K	Hold	4,000	–	–	﹤0.01%	420
2022 Q1	$29K	Hold	4,000	–	–	0.01%	348
2021 Q4	$22K	Hold	4,000	–	–	﹤0.01%	374
2021 Q3	$26K	Sell	4,000 -1,000	-20%	-$6.43K	0.01%	352
2021 Q2	$42K	Hold	5,000	–	–	0.01%	320
2021 Q1	$52K	Buy	5,000 +1,000	+25%	+$14.1K	0.01%	298
2020 Q4	$68K	Buy	+4,000	New	+$60K	0.01%	244

Other funds holding PRVB

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Dividend Assets Capital's PRVB Position: Q2 2023 in Review

Dividend Assets Capital sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 4,000 shares — an estimated $42K sold.

Dividend Assets Capital first reported a position in PRVB in Q4 2020 and held it in 10 quarters. The position peaked at $68K in Q4 2020. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

Dividend Assets Capital reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Dividend Assets Capital sold 4,000 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $42K.
Dividend Assets Capital first reported a position in Provention Bio, Inc. Common Stock in Q4 2020 and held it in 10 quarters.
Dividend Assets Capital's Provention Bio, Inc. Common Stock position peaked at $68K in Q4 2020.
1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on Dividend Assets Capital's 13F filing for Q2 2023, filed 31 Jul 2023.